Compare · HYPR vs SLNO
HYPR vs SLNO
Side-by-side comparison of Hyperfine Inc. (HYPR) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HYPR and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 27.7x HYPR ($99.7M).
- Over the past year, HYPR is down 53.6% and SLNO is down 17.5% - SLNO leads by 36.1 points.
- HYPR has hit the wire 4 times in the past 4 weeks while SLNO has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 4 for HYPR).
- Company
- Hyperfine Inc.
- Soleno Therapeutics Inc.
- Price
- $0.93-0.51%
- $53.02+0.08%
- Market cap
- $99.7M
- $2.76B
- 1M return
- +18.18%
- +0.76%
- 1Y return
- -53.62%
- -17.50%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2014
- News (4w)
- 4
- 0
- Recent ratings
- 4
- 12
Hyperfine Inc.
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest HYPR
- SEC Form 8-K filed by Hyperfine Inc.
- Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026
- Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million
- Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets
- Hyperfine Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents
- Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference
- Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans
- Chief Operating Officer Teisseyre Thomas sold $6,273 worth of shares (7,345 units at $0.85), decreasing direct ownership by 1% to 671,256 units (SEC Form 4) to cover withholding tax
- CFO and CAO Hale Brett sold $6,273 worth of shares (7,345 units at $0.85), decreasing direct ownership by 1% to 592,420 units (SEC Form 4) (tax withholding)
Latest SLNO
- Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)